Integra Biosciences Acquires Biotechnology Specialist Miroculus to Advance Genomics Discoveries
|
By LabMedica International staff writers Posted on 20 Mar 2023 |

Next-generation sequencing (NGS) is a rapid and inexpensive approach for examining the genome - the entire set of an organism's DNA. It has gained immense popularity since its inception almost two decades ago due to its throughput, speed, cost-effectiveness, and capacity to scale it up for larger projects. Consequently, NGS has transformed the spheres of genomic diagnostics, environmental science, reproductive health, forensics, and agriculture in recent times.
INTEGRA Biosciences (Hudson, NH, USA) has acquired Miroculus (San Francisco, CA, USA), a biotech company focused on developing automation solutions that streamline NGS protocols. The acquisition will allow INTEGRA to extend its reach in the growing NGS market, providing novel process automation solutions to assist academic, research and diagnostics laboratories in saving time and speeding up discovery in this dynamic field.
Miroculus was set up with the objective of conceiving inventive and exclusive tools to enable high-quality scientific research worldwide. The company has extensive expertise in the fields of biochemistry, bioanalytics, molecular biology, and materials science. Miroculus began by developing a prototype system for miRNA detection, but soon recognized the technology’s potential for other applications, particularly for automating complex genomics protocols and making them easier and more accessible. Currently, Miroculus focuses on creating intuitive and flexible platforms based on its patented technology, simplifying complex NGS protocols and enabling researchers to translate their discoveries into practical solutions that are accessible to everyone.
The acquisition will boost company growth and unlock new opportunities for INTEGRA and Miroculus. INTEGRA expects the initiation of various genomics-based initiatives soon and is confident that the acquisition will contribute significantly to advancing scientific discovery in the vital field of genomics.
“The global NGS market has been growing exponentially in recent years, and seems set to continue doing so,” said Urs Hartmann, CEO of INTEGRA. “We have acquired this promising start-up because we recognize the huge potential of its revolutionary digital microfluidics technology for automating and miniaturizing genomic protocols. Miroculus' proprietary platform delivers assay flexibility and automation capacity, which enables seamless workflow integration. This will help to remove process bottlenecks and advance science – one of INTEGRA’s primary goals.”
“Bringing Miroculus under our company umbrella will allow us to benefit from the company’s expertise and wealth of knowledge surrounding NGS in particular,” added Urs. “This in-depth genetic analysis know-how will help us to rapidly expand our range of genomics solutions, creating novel platforms for applications such as automating long-read sequencing and target enrichment protocols. Miroculus’ vision and technology complement our own innovative solutions, making it the perfect fit for our company as we dive deeper into the genomics sector and establish a competitive edge for ourselves in this flourishing segment. We're very much looking forward to welcoming all of the Miroculus team into the INTEGRA family, and we are confident that our combined talents will allow us to support the growing needs in the genetics arena by developing revolutionary and unique tools.”
“We began Miroculus with the mission to advance science and improve lives faster, and the last year has been very eventful for us as we’ve worked to achieve this goal,” said Alejandro Tocigl, Co-Founder and CEO of Miroculus. “Most notably, we launched the Miro Canvas system, a revolutionary digital microfluidics platform that fully automates NGS sample preparation protocols. We are extremely excited that the Miroculus team will now be a part of the INTEGRA group, and this acquisition will continue our shared culture of innovation for the scientific community.”
Related Links:
INTEGRA Biosciences
Miroculus
Latest Industry News
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
- GSI Group Acquires Blood Processing Equipment Manufacturer GenesisBPS
- ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases
- Lumiquick Acquires Aoxre to Expand Global IVD and Research Capabilities
- Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics
- Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
New Blood Biomarkers Help Diagnose Pregnancy-Linked Liver Complication
Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disorder linked to pregnancy and can pose serious risks for both mother and baby, including premature delivery and stillbirth.... Read more
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read more
Common Health Issues Can Influence New Blood Tests for Alzheimer’s Disease
Blood-based tests for Alzheimer’s disease are transforming diagnosis by offering a simpler alternative to spinal taps and brain imaging. However, many people evaluated at memory clinics also live with... Read more
Blood Test Formula Identifies Chronic Liver Disease Patients with Higher Cancer Risk
Chronic liver disease affects millions worldwide and can progress silently to hepatocellular carcinoma (HCC), one of the deadliest cancers globally. While surveillance guidelines exist for patients with... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more








